The N-terminal Moiety of CDC25Mm, a GDP/GTP Exchange Factor of Ras Proteins, Controls the Activity of the Catalytic Domain
MODULATION BY CALMODULIN AND CALPAIN*

(Received for publication, October 3, 1996, and in revised form, December 10, 1996)

Soria Baouz Dagger , Eric Jacquet , Alberto Bernardi § and Andrea Parmeggiani

From the Groupe de Biophysique-Equipe 2, Ecole Polytechnique, F-91128 Palaiseau Cedex, France and § Laboratoire d'Enzymologie du Centre National de la Recherche Scientifique, F-91198 Gif-sur-Yvette and Institut Jacques Monod, Université Paris 7, F-75251 Paris 05, France

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES


ABSTRACT

This work describes the in vitro properties of full-length CDC25Mm (1262 amino acid residues), a GDP/GTP exchange factor (GEF) of H-ras p21. CDC25Mm, isolated as a recombinant protein in Escherichia coli and purified by various chromatographic methods, could stimulate the H-ras p21·GDP dissociation rate; however, its specific activity was 25 times lower than that of the isolated catalytic domain comprising the last C-terminal 285 residues (C-CDC25Mm285) and 5 times lower than the activity of the C-terminal half-molecule (631 residues). This reveals a negative regulation of the catalytic domain by other domains of the molecule. Accordingly, the GEF activity of CDC25Mm was increased severalfold by the Ca2+-dependent protease calpain that cleaves around a PEST-like region (residues 798-853), producing C-terminal fragments of 43-56 kDa. In agreement with the presence of an IQ motif on CDC25Mm (residues 202-229), calmodulin interacted functionally with the exchange factor. Depending on the calmodulin concentration an inhibition up to 50% of the CDC25Mm-induced nucleotide exchange activity on H-ras p21 was observed, an effect requiring Ca2+ ions. Calmodulin also inhibited C-CDC25Mm285 but with a ~100 times higher IC50 than in the case of CDC25Mm (~10 µM versus 0.1 µM, respectively). Together, these results emphasize the role of the other domains of CDC25Mm in controlling the activity of the catalytic domain and support the involvement of calmodulin and calpain in the in vivo regulation of the CDC25Mm activity.


INTRODUCTION

The mouse CDC25Mm 1 protein is a guanine nucleotide exchange factor (GEF) regenerating the active form of H-ras p21, the complex with GTP (1-3). Homologous products were found in rat (p140-rasGRF) (4) and human (H-GRF) (5, 6). These rasGEFs have been described to be specific for the central nervous system (4-9). Some evidence has also been reported for the existence of full-length and truncated forms of these exchange factors in other tissues (10, 11). Experiments in vivo suggest that the upstream connection of this GEF involves G-protein-coupled receptors (9, 12, 13) and not hormone-receptor-bound tyrosine kinases via the adaptor protein GRB2, as has been found for SOS, a ubiquitous rasGEF (14-16). CDC25Mm contains in the N-terminal moiety two domains of pleckstrin homology (PH1 and PH2), one of DBL homology (DH) and a coiled-coil region that follows the PH1 domain (cf. Ref. 17). PH domains are frequently present in signaling proteins and represent regions of interactions with specific ligands such as the beta gamma -subunits of heterotrimeric G-proteins (18, 19) and phospholipids (20). Coiled-coils are specific tertiary structures involved in protein interactions (21) and the DH is a domain sharing similarity with a GDP/GTP exchange factor of members of the Rho family (2, 4, 22, 23). Farnsworth et al. (24) reported that in vivo the activity of the homologous p140-rasGRF from rat brain is enhanced by raising the calcium concentration, an effect associated with the binding of calmodulin, and that p140-rasGRF and calmodulin form a stable complex. A direct action of calmodulin was supported by the presence in the N-terminal region of CDC25Mm of an IQ domain, a sequence frequently found in proteins interacting with calmodulin (25, 26). Very recent experiments in vivo have indicated that PH1, coiled-coil and IQ domains act cooperatively to facilitate the activation of p140-rasGRF by calcium (17). Moreover, the presence in p140-rasGRF of two adjacent PEST sequences has suggested potential cleavage by the Ca2+-dependent protease calpain (26). Concerning in vitro properties, whereas C-terminal catalytic fragments spanning 256 to 488 amino acid residues have been biochemically characterized (3, 5, 27, 28), little is known about the functional properties in vitro of the full-length molecule comprising 1262 (CDC25Mm) or 1244 (p140-rasGRF) amino acid residues, of which the purification has yet to be reported.

Therefore, with the aim at deepening our knowledge of the mechanisms controlling the activation of H-ras p21, we have produced and purified the full-length CDC25Mm as recombinant protein in Escherichia coli and characterized its properties under well defined conditions in vitro. The purified GEF shows a specific activity much lower than its isolated catalytic domain or the C-terminal half-molecule; it is inhibited by calmodulin and is specifically cleaved by calpain.


MATERIALS AND METHODS

Production and Purification of CDC25Mm

The entire open reading frame of murine CDC25Mm gene from a BamHI-EcoRI fragment of pHC28 (22) was cloned in a pGEX2TH in which the HindIII site had been replaced by a SalI site. A BamHI-SalI fragment, containing the total CDC25Mm gene, was cloned in BamHI-SalI of pMAL-c2 (New England Biolabs) and expressed in E. coli strain SCS1 as N-terminal fusion with the maltose-binding-protein (MBP), comprising a Xa-specific cleavage site. Cell cultures (1.5 liters) were grown at 30 °C in LB medium containing 50 µg/ml ampicillin. The induction was started with 0.1 mM isopropyl-beta -D-thiogalactopyranoside at a cell density of 0.2 A600 units and continued at 24 °C to a density of 1.5 A600 units. After centrifugation (7,000 × g for 10 min), the resuspended pellet was sonicated 5 times for 15 s in buffer A (25 mM Tris-HCl, pH 7.5, 50 mM NaCl, 7 mM ME) containing 10% glycerol, 1 mM EDTA, and 1 mM Pefablock-SC and centrifuged for 20 min at 25,000 × g at 4 °C, a temperature at which all the subsequent purification steps were carried out. The supernatant was loaded on a 6-ml ResourceQ column (fast protein liquid chromatography system, Pharmacia Biotech Inc.) equilibrated with buffer A and eluted with the same buffer at a flow rate of 3 ml/min. Unlike the bulk of E. coli proteins, the largest portion of MBP-CDC25Mm was not retained on the resin. The nonretained active fractions were mixed with 10 ml of amylose-resin (New England Biolabs) equilibrated in buffer A and gently shaken for 30 min. After centrifugation at low speed (2,500 × g for 2 min), the supernatant was discarded, and the resin mixed again with 50 ml of buffer A was centrifuged. This step was repeated four times. Finally, MBP-CDC25Mm was removed from the amylose resin by two washes with 10 ml of buffer A containing 10 mM maltose. After centrifugation, the combined supernatants were passed on a HiTrap heparin column of 5 ml (Pharmacia) that was step-eluted with 250, 400, 600, and 1000 mM NaCl solutions in 25 mM Tris-HCl, pH 7.5, and 7 mM ME (flow rate: 5 ml/min) under control of the fast protein liquid chromatography system. MBP-CDC25Mm emerged at 600 mM NaCl. After dialysis against buffer A plus 50% glycerol, the purest fractions on SDS-PAGE, were stored at -20 °C. Their activity was stable for at least 6 months.

Assay for GEF Activity

The dissociation rates of the p21·[3H]GDP complexes were measured kinetically at 30 °C after addition of a 500-fold excess of unlabeled nucleotide using the nitrocellulose binding assay. The labeled p21·[3H]GDP was prepared by incubation for 5 min at 30 °C in 100 µl of buffer B (50 mM Tris-HCl, pH 7.5, 1 mM MgCl2, 100 mM NH4Cl and 0.5 mg·ml-1 bovine serum albumin), containing 2 µM p21, 3 mM EDTA, and 6 µM [3H]GDP (350 Bq·pmol-1, DuPont NEN). Then, 3 mM MgCl2 was added. The reaction mixture for the dissociation experiments contained, in buffer B, 0.1-0.2 µM p21·[3H]GDP and either MBP-CDC25Mm, GST-C-CDC25Mm631, or C-CDC25Mm285, calmodulin, calpain, CaCl2, or EGTA as indicated in the legends to figures. The concentration of glycerol carried over from the CDC25Mm storage buffer was maximally 10%. An equal amount of storage buffer was added to the control. For calpain treatment see legend to Fig. 4 or the text in the relative section of "Results." At the given times, the samples (5-10 µl) were filtered through nitrocellulose discs (Sartorius 11306, 0.45 µm), washed twice with 3 ml of ice-cold 50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, and 100 mM NH4Cl, and the retained p21-bound radioactivity was measured in a liquid scintillation counter LKB/Pharmacia, model Wallac 1410. 


Fig. 4. Calpain-treatment of CDC25Mm generates C-terminal fragments (A) enhancing the GEF activity (B). A, Western blot performed with anti-C-CDC25Mm285 antibodies. The digestion time at 30 °C was 5 min in a buffer containing 50 mM Tris-HCl, pH 7.5, 1 mM MgCl2, 100 mM NH4Cl, 2 mM CaCl2, 0.1 µM CDC25Mm, and 1 µM calpain. Lane 1, untreated CDC25Mm; lane 2, asterisks indicate the C-terminal fragments appearing after treatment with calpain. Note: calpain displays a slight unspecific response to polyclonal anti-C-CDC25Mm antibodies. B, the concentration of calpain was 1 µM and of CaCl2 2 mM. The digestion time at 30 °C was 3 min. Dissociation rates of p21·[3H]GDP in the absence of CDC25Mm (square ) or in the presence of 0.1 µM CDC25Mm without (black-triangle) and with (triangle ) treatment with calpain.
[View Larger Version of this Image (19K GIF file)]


Other Materials and Methods

C-CDC25Mm285 and human c-H-ras p21 were isolated and purified as described (27, 29). C-CDC25Mm631 was produced in E. coli, as GST fusion and purified by affinity chromatography on glutathione-Sepharose, under the same conditions as reported for C-CDC25Mm285 by Jacquet et al. (27). This was followed by chromatography on HiTrap Heparin column (see above). Stepwise elution of C-CDC25Mm631 took place at 400 mM NaCl. Calmodulin and calpain were purchased from Sigma. SDS-PAGE was carried out using a 10%/0.25% acrylamide/bisacrylamide gel and stained with Coomassie Blue. The anti-C-CDC25Mm285 antibodies were produced in rabbit, and those anti-MBP were purchased from New England Biolabs. Protein concentration was determined by the Bio-Rad assay, using bovine serum albumin as a standard. The concentration of p21 was checked by [3H]GDP binding. To determine the percentage of protein components, Coomassie Blue-stained gels were analyzed with the Apple scanner system, and the results were evaluated with the Scan Analysis software.


RESULTS

Purification of CDC25Mm and C-CDC25Mm631

Cloning of the full-length CDC25Mm gene in pGEX resulted in low expression and little soluble product, whereas the use of a pMAL vector allowed the production of ~1 mg of CDC25Mm/1 liter of cell culture at a A600 cell density of 1.5 units. More than 60% of the produced CDC25Mm remained soluble after a 20-min centrifugation at 25,000 × g. The temperature of induction was important; incubation at 24 °C gave higher concentrations of soluble CDC25Mm than at 37 °C. On SDS-PAGE the MBP-fused product showed the expected apparent molecular mass of 188 kDa and corresponded, after purification, to the slowest migrating band (~50% of the total proteins) (Fig. 1A, lane 4). In the purified preparations, Western blot with anti-C-CDC25Mm285 antibodies revealed only one band corresponding to the molecular mass of the MBP-fused full-length protein (188 kDa) (Fig. 1B, lane 2) while most other SDS-PAGE bands were responsive to anti-MBP antibodies (Fig. 1B, lane 1). Since no proteolysis was detectable in the cell extract, these bands consist of N-terminal incomplete translational products of MBP-CDC25Mm. Accordingly, a second passage on amylose resin gave the same gel pattern without any further purification. Also the use of other chromatographic techniques such as ionic exchange (ResourceQ, Pharmacia, at pH from 7.0 to 9.5) and hydrophobic resins (Pharmacia kit), or of hydroxylapatite and filtration methods (Superdex, Pharmacia and Microcon-100, Amicon) did not improve purification. Together, these properties show that our CDC25Mm preparations were not contaminated by C-terminal fragments and contained little, if any, E. coli proteins. Protein concentration by means of Aquacide II or Amicon ultrafiltration was avoided, since it caused loss of activity, likely due to aggregation. Cleavage of the fused MBP by factor Xa led to degradation of CDC25Mm; therefore, we have used the fused protein. C-CDC25Mm631 was obtained >90% pure as GST-fused protein. C-CDC25Mm285 was homogeneous on SDS-PAGE, as reported (27).


Fig. 1. SDS-PAGE of MBP-CDC25Mm prior to and after purification (A) and Western blot with anti-MBP or antiC-CDC25Mm-285 antibodies (B). A, SDS-PAGE of molecular weight markers (lane 1), total cell extract prior to induction of MBP-CDC25Mm (lane 2), total cell extract after induction of MBP-CDC25Mm (lane 3), purified preparation of MBP-CDC25Mm (lane 4). B, Western blots of purified preparation of MBP-CDC25Mm revealed with anti-MBP (lane 1) and with anti-C-CDC25Mm285 antibodies (lane 2).
[View Larger Version of this Image (62K GIF file)]


Comparison of the Activities of Full-length CDC25Mm, C-CDC25Mm631, and C-CDC25Mm285

Experiments in vivo suggest that CDC25Mm has a constitutive GEF activity (9). In line with this, the [3H]GDP/GDP exchange rate of p21·[3H]GDP in vitro was enhanced by the purified full-length CDC25Mm (Fig. 2A). The stimulation of the p21·GDP dissociation rate constant increased linearly with increasing the CDC25Mm concentration (Fig. 2B). Fig. 2C shows that the C-terminal half-molecule C-CDC25Mm631 displayed a constitutive GEF activity several times higher than the full-length molecule. Also in this case, increasing concentrations of C-CDC25Mm631 enhanced linearly the GDP/GDP exchange activity of H-ras p21 (Fig. 2D). Similar results were obtained by determining the GDP/GTP exchange rate (not shown).


Fig. 2. [3H]GDP/GDP exchange rate of H-ras p21 and stimulation of the dissociation rate constants of H-ras p21·GDP as a function of CDC25Mm or C-CDC25Mm631 concentration. The reaction mixture contained 0.2 µM H-ras p21·[3H]GDP minus (square ) and plus (black-square) 0.140 µM CDC25Mm (A) or 0.040 µM C-CDC25Mm631 (C). The same conditions were used to determine kinetically the dissociation rate constants and the stimulation factor as a function of the concentration of CDC25Mm (0.025 to 0.200 µM, panel B) and C-CDC25Mm631 (0.010 to 0.120 µM, panel D).
[View Larger Version of this Image (24K GIF file)]


The activity of CDC25Mm and C-CDC25Mm631 was then compared with that of the C-terminal fragment C-CDC25Mm285, the best studied catalytic fragment of CDC25Mm (3, 27), slightly longer than the shortest catalytic domain isolated so far (last 256 C-terminal residues, ref 28). C-CDC25Mm285 was by far the most active of the three rasGEF forms. At a concentration of 0.2 µM, the activities of CDC25Mm and C-CDC25Mm631 were 4.4 and 23%, respectively, that of C-CDC25Mm285 (Fig. 3). This reveals a negative influence on the activity of the C-terminal domain by other domains of CDC25Mm.


Fig. 3. Comparison of the GEF activity of CDC25Mm, C-CDC25Mm631, and C-CDC25Mm285 as determined from the stimulation of the dissociation rate constants of H-ras p21·[3H]GDP. The concentration of the GEF forms was 0.2 µM. Open bar, C-CDC25Mm285; shaded bar, C-CDC25Mm631; solid bar, CDC25Mm .
[View Larger Version of this Image (20K GIF file)]


CDC25 Mm is specifically cleaved by calpain around a PEST region

Cheney and Mooseker (26) identified in the homologous p140-rasGRF from rat two adjacent PEST sequences located between residues 792 and 836. PEST sequences have been proposed to confer rapid degradation to numerous proteins via the Ca2+-dependent protease calpain (30, 31). To determine whether this was also the case for CDC25Mm, the action of calpain was examined by determining its proteolytic effect and the possible consequences on the GEF activity. On Western blot (Fig. 4A), we observed with anti-C-CDC25Mm285 antibodies that digestion of CDC25Mm by calpain induced the appearance of two to four C-terminal fragments with a molecular mass between 43 and 56 kDa. Digestion of CDC25Mm at 30 °C proceeded rapidly: >90% in 2 min with 1 µM calpain and 50% in 30 min with 0.05 µM calpain. No cleavage of C-CDC25Mm285 by calpain could be detected.

As shown in Fig. 4B, calpain-treated CDC25Mm showed a ras GEF activity ~3 times as strong as that of the untreated CDC25Mm. This effect, clearly dependent on the production of C-terminal CDC25Mm fragments with constitutive activities higher than the activity of the full-length molecule, further confirms the negative influence of the N-terminal moiety on the activity of the C-terminal catalytic domain and suggests a regulatory role by proteases on the activity of this rasGEF.

Calmodulin Action on CDC25Mm Activity

Farnsworth et al. (24) observed that H-ras p21 activation by p140-rasGRF in vivo was enhanced by raising the concentration of Ca2+, a mechanism mediated by calmodulin, since this ubiquitous protein, known to be involved in cellular processes controlled by Ca2+-dependent signaling (cf. Refs. 32 and 33), was coprecipitated with p140-rasGRF. The fact that CDC25Mm has the same recognition sequence for calmodulin (IQ motif, residues 202-229), as found in p140-rasGRF (residues 198-225T) (26) suggests a productive interaction also between CDC25Mm and calmodulin. As shown in Fig. 5, in our in vitro system Ca2+-calmodulin was found to inhibit the rasGEF activity of CDC25Mm. With increasing concentrations of calmodulin, the inhibition leveled at ~50% the rasGEF activity, the concentration of calmodulin inducing half maximum inhibition (IC50) being ~0.1 µM (Fig. 5, inset).


Fig. 5. Inhibition of the activity of CDC25Mm by Ca2+-calmodulin. The reaction mixtures containing 2 mM CaCl2 were incubated for 3 min at 30 °C with or without 0.15 µM CDC25Mm and increasing concentrations of calmodulin from 0.05 to 5 µM, as indicated. Thereafter, the dissociation reaction was started by the addition of 0.2 µM p21·[3H]GDP complex. The dissociation rate constants are represented by bars. Inset, percentage of inhibition as a function of increasing concentrations of calmodulin.
[View Larger Version of this Image (40K GIF file)]


In experiments not shown, we have observed that the treatment of CDC25Mm by calpain leading to N-terminal and C-terminal-truncated fragments abolished the inhibition of the GEF activity induced by 1 µM calmodulin. Thus, one can conclude that the inhibitory effect of calmodulin on the catalytic activity of the C-terminal domain is due to an intramolecular mechanism originating from the N-terminal moiety.

As shown in Fig. 6, the omission of Ca2+ and the addition of 0.1 mM EGTA led to a progressive slight decrease of the calmodulin inhibition on the CDC25Mm activity, the obtained values displaying a marked variability. Only at 1 mM EGTA, the calmodulin effect was completely abolished.


Fig. 6. Influence of calcium on the calmodulin-dependent inhibition of CDC25Mm activity. The inhibition by calmodulin (1 µM) on the p21·[3H]GDP dissociation rate stimulated by CDC25Mm (0.2 µM) was measured in buffer B containing CaCl2 or EGTA as indicated. The reaction was started by the addition of the p21·[3H]GDP complex. The 100% CDC25Mm activity refers to the values obtained in the absence of calmodulin under the same experimental conditions. The values represent the mean of 10 experiments.
[View Larger Version of this Image (63K GIF file)]


Ca2+-calmodulin also inhibited the GEF activity of C-CDC25Mm285, but at a concentration about 100 times higher than in the case of the full-length molecule (IC50 = ~10 versus 0.1 µM, respectively) (Fig. 7). Calmodulin had no effect on the intrinsic GDP exchange activity of H-ras p21.


Fig. 7. Calmodulin can interact with the catalytic domain of CDC25Mm. The p21·[3H]GDP dissociation kinetics were determined in buffer B containing 2 mM CaCl2 in the presence of 0.01 µM C-CDC25Mm285 and increasing concentrations of calmodulin as indicated. The reaction was started by the addition of p21·[3H]GDP complex to a final concentration of 0.2 µM.
[View Larger Version of this Image (17K GIF file)]



DISCUSSION

The biochemical characterization of purified full-length CDC25Mm shows that its noncatalytic moiety, comprising two PH, one DH, one coiled-coil and one IQ domain, has a regulatory function on the GEF activity of CDC25Mm. In fact, the specific activity of the full-length protein is ~4% that of the isolated catalytic C-terminal fragment of 285 residues. The observation that the C-terminal half-molecule shows an activity, whose extent lies between the activity of the full-length CDC25Mm and that of C-CDC25Mm285, further confirms a regulatory function of the noncatalytic moiety of the molecule and supports the existence in the cell of mechanisms activating this GEF. This is in agreement with experiments in vivo showing that serum stimulation of NIH3T3 transformants leads to an increase in Ras·GTP only in cells expressing the entire CDC25Mm but not in cells expressing smaller C-terminal forms of CDC25Mm (9, 22). Thus, the N-terminal region is essential for the response to serum. In line with this, is also the observation that the C-terminal truncated CDC25Mm lacking the last 600 amino acids behaves as dominant negative to the response to serum of the full-length molecule (9).

The specific cleavage by calpain around the PEST region increases the GEF activity due to the production of C-terminal fragments. The observation that the induced activity is of the same range as the activities of C-CDC25Mm631 and the p140-rasGRF C-terminal fragment of 456 residues (4) suggests that most noncatalytic domains participate in regulating the activity of the catalytic C-terminal conserved region. This indicates that the signal activating the productive interaction between the CDC25Mm C-terminal region and H-ras p21 evokes a global effect on the CDC25Mm molecule.

It is known that the activity of calpain can be coordinated with that of calmodulin, as shown by the frequent presence on calmodulin-binding proteins of a PEST motif and the functional relationship between calpain action and calmodulin binding site (cf. Ref. 34). In a large number of proteins (cf. Refs. 30 and 31), PEST sequences appear to represent a signal for rapid degradation by non-ubiquitin-mediated proteolysis that can involve calpain. Interestingly, in the mouse embryo brain a 58-kDa form of CDC25Mm was described, whereas in the more slowly metabolizing adult brain only the full-length 140-kDa protein could be detected (7). In the human brain, besides the full-length 140-kDa H-GRF, shorter forms of 43-50 kDa were reported (5) that might also be present in tissues other than brain (11). The results of our work show that C-terminal CDC25Mm fragments of 43-56 kDa can originate from the action of calpain. Therefore, as reported in this work, activation of the GEF activity by calpain appears to be mediated by C-terminal fragments that are more active than the full-length molecule. In vivo, an eventual action of calpain could contribute to modulate the activity of CDC25Mm. In this context, it is worth mentioning that the expression of C-CDC25Mm285 in fibroblasts was found to enhance the GDP/GTP exchange activity on H-ras p21 and the tumor formation in the nude mice (35). Moreover, the homologous Saccharomyces cerevisiae rasGEF Cdc25p, containing a cyclin destruction box, has been described to display a rapid metabolism (half-life time, ~20 min) due to proteolytic degradation (36). Whether proteases also act on the mammalian rasGEF in vivo remains to be determined, since the half-life of CDC25Mm in neuronal cells is still unknown.

From our results, Ca2+-calmodulin interacts efficiently with CDC25Mm, inhibiting the rasGEF activity with a IC50 of 0.1 µM, an effect dependent on Ca2+, corresponding approximately to an equimolar ratio between calmodulin and CDC25Mm. The course of inhibition with increasing amounts of calmodulin suggests a noncompetitive effect on the GEF activity of CDC25Mm. Hence, binding of calmodulin and p21 to CDC25Mm should concern distinct sites. The weak interaction of calmodulin with the catalytic domain of CDC25Mm suggests the possibility that in the three-dimensional conformation the IQ sequence at the N-terminal region (residues 202-229) and the C-terminal catalytic domain are vicinal.

Calmodulin is in general known to activate calmodulin-binding proteins. However, in some cases such as calmodulin-kinase II, calmodulin-kinase IV, myosin light chain kinase and calcineurin, incubation with Ca2+/calmodulin has been shown to induce inactivation (cf. Refs. 37 and 38). It is interesting to mention that calmodulin-kinase IV interacts with calmodulin with high affinity, comparable to that of CDC25Mm (37), differently from calmodulin-kinase II which is inhibited only by high concentration of calmodulin (38).

Noteworthy is the relatively high concentration of EGTA required for abolishing the Ca2+-calmodulin-dependent effect. Several recent studies have indicated that the conformation of the N-terminal and C-terminal calcium binding helix-loop-helix motifs of calmodulin depends on whether calcium-is bound or not (cf. Ref. 39). Since the affinity of EGTA for calcium is several orders of magnitude higher than that of calmodulin, this finding suggests that, when occupied, the Ca2+-binding site of calmodulin is little accessible to the chelating agent.

From experiments in vivo (24), one would rather expect that Ca2+-calmodulin activates CDC25Mm. This difference with our results in vitro suggests the existence of other components affecting the action of calmodulin on CDC25Mm in the cell implying a more complex calmodulin-regulated mechanism. The same authors (24) report that calmodulin-bound p140-rasGRF isolated from stimulated cells and calmodulin-free p140-rasGRF isolated from unstimulated cells display the same GEF activity. The different experimental conditions may be the reason for the discrepancy between these and our results.

In conclusion, our work supports a regulatory role of the N-terminal moiety of CDC25Mm on its catalytic domain and suggests that calmodulin and calpain act as modulators of the CDC25Mm activity in the cell. Very recently, Mattingly and Macara (13) have reported on the basis of experiments in vivo a phosphorylation-dependent activation of CDC25Mm exchange factor by muscarinic receptors and G-protein beta gamma -subunits. The relationship between this effect and the calmodulin-dependent regulation remains an open question.


FOOTNOTES

*   This work was supported by the European Community (contract: BIOTECH BIO2-CT93-00005), Ligue Nationale Française Contre le Cancer, Association pour la Recherche sur le Cancer (Grant 6377), Fédération Nationale des Centres de Lutte Contre le Cancer and Groupement de Recherches et d'Etudes sur les Génomes.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    Supported by a fellowship of the Association pour la Recherche sur le Cancer.
   To whom correspondence should be addressed: Groupe de Biophysique-Equipe 2, Ecole Polytechnique, F-91128 Palaiseau Cedex, France. Tel.: 33-1-6933-4180; Fax: 33-1-6933-4840.
1   The abbreviations used are: CDC25Mm, full-length murine CDC25Mm gene product of 1262 amino acid residues; C-CDC25Mm285 and C-CDC25Mm631, C-terminal fragments of CDC25Mm comprising the last 285 and 631 amino acid residues, respectively; MBP, maltose-binding protein; GEF, guanine nucleotide exchange factor; GRF, guanine nucleotide releasing factor; ME, 2-mercaptoethanol; PAGE, polyacrylamide gel electrophoresis; GST, glutathione S-transferase.

Acknowledgments

We are indebted to Dr. D. R. Lowy for sending the CDC25Mm gene cloned in pHC28 and Drs. J. B. Créchet, M.C. Parrini, C. Giglione, and I. M. Krab for fruitful discussion and advice.


REFERENCES

  1. Martegani, E., Vanoni, M., Zippel, R., Coccetti, P., Brambilla, R., Ferrari, C., Sturani, E., and Alberghina, L. (1992) EMBO J. 11, 2151-2157 [Abstract]
  2. Cen, H., Papageorge, A. G., Zippel, R., Lowy, D. R., and Zhang, K. (1992) EMBO J. 11, 4007-4015 [Abstract]
  3. Jacquet, E., Vanoni, M., Ferrari, C., Alberghina, L., Martegani, E., and Parmeggiani, A. (1992) J. Biol. Chem. 267, 24181-24183 [Abstract/Free Full Text]
  4. Shou, C., Farnsworth, C. L., Neel, B. G., and Feig, L. A. (1992) Nature 358, 351-354 [CrossRef][Medline] [Order article via Infotrieve]
  5. Schweighoffer, F., Faure, M., Fath, I., Chevallier-Multon, M.-C., Apiou, F., Dutrillaux, B., Sturani, E., Jacquet, M., and Tocque, B. (1993) Oncogene 8, 1477-1485 [Medline] [Order article via Infotrieve]
  6. Wei, W., Das, B., Park, W., and Broek, D. (1994) Gene (Amst.) 151, 279-284 [CrossRef][Medline] [Order article via Infotrieve]
  7. Martegani, E., Zippel, R., Ferrari, C., Coccetti, P., Campiglio, S., Denis-Donini, S., Sturani, E., Vanoni, M., and Alberghina, L. (1993) Eur. J. Histochem. 37, 73-78
  8. Ferrari, C., Zippel, R., Martegani, E., Gnesutta, N., Carrera, V., and Sturani, E. (1994) Exp. Cell Res. 210, 353-357 [CrossRef][Medline] [Order article via Infotrieve]
  9. Zippel, R., Orecchia, S., Sturani, E., and Martegani, E. (1996) Oncogene 12, 2697-2703 [Medline] [Order article via Infotrieve]
  10. Chen, L., Zhang, L.-J., Greer, P., Tung, P. S., and Moran, M. F. (1993) Dev. Genet. 14, 339-346 [Medline] [Order article via Infotrieve]
  11. Guerrero, C., Rojas, J. M., Chedid, M., Esteban, L. M., Zimonjic, D. B., Popescu, N. C., Font de Mora, J., and Santos, E. (1996) Oncogene 12, 1097-1107 [Medline] [Order article via Infotrieve]
  12. Shou, C., Wurmser, A., Ling, K., Barbacid, M., and Feig, L. A. (1995) Oncogene 10, 1887-1893 [Medline] [Order article via Infotrieve]
  13. Mattingly, R. R., and Macara, I. G. (1996) Nature 382, 268-272 [CrossRef][Medline] [Order article via Infotrieve]
  14. Chardin, P., Camonis, J. H., Gale, N. W., Van Aelst, L., Schlessinger, J., Wigler, M. H., and Bar-Sagi, D. (1993) Science 260, 1338-1343 [Medline] [Order article via Infotrieve]
  15. Egan, S. E., Giddings, B. W., Brooks, M. W., Buday, L., Sizeland, A. M., and Weinberg, R. A. (1993) Nature 363, 45-51 [CrossRef][Medline] [Order article via Infotrieve]
  16. Gale, N. W., Kaplan, S., Lovenstein, E. J., Schlessinger, J., and Bar-Sagi, D. (1993) Nature 363, 88-92 [CrossRef][Medline] [Order article via Infotrieve]
  17. Buchsbaum, R., Telliez, J.-B., Goonesekera, S., and Feig, L. A. (1996) Mol. Cell. Biol. 16, 4888-4896 [Abstract]
  18. Musacchio, A., Gibson, T., Rice, P., Thompson, J., and Saraste, M. (1993) Trends Biochem. Sci. 18, 343-348 [CrossRef][Medline] [Order article via Infotrieve]
  19. Inglese, J., Koch, W. J., Touhara, K., and Lefkowitz, R. J. (1995) Trends Biochem. Sci. 20, 151-155 [CrossRef][Medline] [Order article via Infotrieve]
  20. Fergusson, K. M., Lemmon, M. A., Sigler, P. B., and Schlessinger, J. (1995) Struct. Biol. 2, 715-718
  21. Lupas, A. (1996) Trends Biochem. Sci. 21, 375-382 [CrossRef][Medline] [Order article via Infotrieve]
  22. Cen, H., Papageorge, A. G., Vass, W. C., Zhang, K., and Lowy, D. R. (1993) Mol. Cell. Biol. 13, 7718-7724 [Abstract]
  23. Hart, M. J., Eva, A., Evans, T., Aaronson, S. A., and Cerione, R. A. (1991) Nature 354, 311-314 [CrossRef][Medline] [Order article via Infotrieve]
  24. Farnsworth, C. L., Freshney, N. W., Rosen, L. B., Ghosh, A., Greenberg, M. E., and Feig, L. A. (1995) Nature 376, 524-527 [CrossRef][Medline] [Order article via Infotrieve]
  25. Cheney, R. E., and Mooseker, M. S. (1992) Curr. Opin. Cell Biol. 4, 27-35 [Medline] [Order article via Infotrieve]
  26. Cheney, R. E., and Mooseker, M. S. (1994) Mol. Biol. Cell Supp. 5, 21A
  27. Jacquet, E., Baouz, S., and Parmeggiani, A. (1995) Biochemistry 34, 12347-12354 [Medline] [Order article via Infotrieve]
  28. Coccetti, P., Mauri, I., Alberghina, L., Martegani, E., and Parmeggiani, A. (1995) Biochem. Biophys. Res. Commun. 206, 253-259 [CrossRef][Medline] [Order article via Infotrieve]
  29. Parrini, M. C., Jacquet, E., Bernardi, A., Jacquet, M., and Parmeggiani, A. (1995) Biochemistry 34, 13776-13783 [Medline] [Order article via Infotrieve]
  30. Reichsteiner, M. (1990) Cell Biol. 1, 433-440
  31. Reichsteiner, M., and Rogers, S. W. (1996) Trends Biochem. Sci. 21, 267-271 [CrossRef][Medline] [Order article via Infotrieve]
  32. Finn, B. E., and Forsén, S. (1995) Structure 3, 7-11 [Medline] [Order article via Infotrieve]
  33. James, P., Vorherr, T., and Carafoli, E. (1995) Trends Biochem. Sci. 20, 38-42 [CrossRef][Medline] [Order article via Infotrieve]
  34. Molinari, M., Maki, M., and Carafoli, E. (1995) J. Biol. Chem. 270, 14576-14581 [Abstract/Free Full Text]
  35. Zippel, R., De Maddalena, C., Porro, G., Modena, D., Sturani, E., and Vanoni, M. (1994) Int. J. Oncol. 4, 175-179
  36. Kaplon, T., and Jacquet, M. (1995) J. Biol. Chem. 270, 20742-20747 [Abstract/Free Full Text]
  37. Kitani, T., Okuno, S., and Fujisawa, H. (1995) J. Biochem. 117, 1070-1075 [Abstract]
  38. Ishida, A., Kitani, T., Okuno, S., and Fujisawa, H. (1994) J. Biochem. 115, 1075-1082 [Abstract]
  39. Swindells, M. B., and Ikura, M. (1996) Nat. Struct. Biol. 3, 501-504 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.